Mezagitamab
- Product Name
- Mezagitamab
- CAS No.
- 2227490-52-8
- Chemical Name
- Mezagitamab
- Synonyms
- Mezagitamab;Mezagitamab (anti-CD38);Research Grade Mezagitamab;Research Grade Mezagitamab (DHD80803)
- CBNumber
- CB68081119
- Formula Weight
- 0
- MOL File
- Mol file
Mezagitamab Property
- form
- Liquid
- color
- Colorless to light yellow
Mezagitamab Chemical Properties,Usage,Production
Uses
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP)[1][2][3].
in vivo
Mezagitamab (0.03-100 mg/kg, iv, once or twice a week for 4-13 weeks) leads to the depletion of NK cells, B cells and T cells in cynomolgus monkey models[4].
Mezagitamab (3 mg/kg, iv,once weekly for 8 weeks) prevents collagen-induced arthritis in cynomolgus monkey models[4].
| Animal Model: | Cynomolgus monkey models[4] |
| Dosage: | 0.03-100 mg/kg |
| Administration: | iv, once or twice a week for 4-13 weeks |
| Result: | Reduced numbers of NK/B/T cells. |
| Animal Model: | Collagen-induced arthritis in cynomolgus monkey models[4] |
| Dosage: | 3 mg/kg |
| Administration: | iv,once weekly for 8 weeks |
| Result: | Inhibited the progression of arthritis. |
References
[1] Abadier M, et al. Mezagitamab induces immunomodulatory effect in patients with relapsed/refractory multiple myeloma (RRMM)[J]. Blood, 2020, 136: 9.
[2] Jadoon Y, et al. Immunotherapy in multiple myeloma. Cancer Treat Res Commun. 2021;29:100468. DOI:10.1016/j.ctarc.2021.100468
[3] Kuter DJ. Novel therapies for immune thrombocytopenia. Br J Haematol. 2022 Mar;196(6):1311-1328. DOI:10.1111/bjh.17872
[4] Roepcke S, et al., Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial. Pharmacol Res Perspect. 2018 Jun;6(3):e00402. DOI:10.1002/prp2.402
[5] Korver W, et al., A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys. J Pharmacol Exp Ther. 2019 Aug;370(2):182-196. DOI:10.1124/jpet.119.256602
Mezagitamab Preparation Products And Raw materials
Raw materials
Preparation Products
Mezagitamab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 400-6206333 13167063860
- anhua.mao@aladdin-e.com
- Country
- China
- ProdList
- 48457
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58